The Relevance of Forest Fragmentation on the Incidence of Human Babesiosis: Investigating the Landscape Epidemiology of an Emerging Tick-Borne Disease

2013 ◽  
Vol 13 (4) ◽  
pp. 250-255 ◽  
Author(s):  
Michael G. Walsh
2003 ◽  
Vol 65 (3) ◽  
pp. 335-340 ◽  
Author(s):  
Satoru ARAI ◽  
Masayoshi TSUJI ◽  
Ikuo KAIHO ◽  
Haruka MURAYAMA ◽  
Aya ZAMOTO ◽  
...  

2014 ◽  
Vol 7 (1) ◽  
Author(s):  
Xia Zhou ◽  
Shang Xia ◽  
Ji-Lei Huang ◽  
Ernest Tambo ◽  
Hong-Xiang Zhuge ◽  
...  

2014 ◽  
Vol 7 (1) ◽  
pp. 509
Author(s):  
Xia Zhou ◽  
Shang Xia ◽  
Ji-Lei Huang ◽  
Ernest Tambo ◽  
Hong-Xiang Ge ◽  
...  

2000 ◽  
Vol 30 (12-13) ◽  
pp. 1323-1337 ◽  
Author(s):  
A.M. Kjemtrup ◽  
P.A. Conrad

Pathogens ◽  
2021 ◽  
Vol 10 (9) ◽  
pp. 1120
Author(s):  
Isaline Renard ◽  
Choukri Ben Mamoun

Babesiosis is an emerging tick-borne disease caused by apicomplexan parasites of the genus Babesia. With its increasing incidence worldwide and the risk of human-to-human transmission through blood transfusion, babesiosis is becoming a rising public health concern. The current arsenal for the treatment of human babesiosis is limited and consists of combinations of atovaquone and azithromycin or clindamycin and quinine. These combination therapies were not designed based on biological criteria unique to Babesia parasites, but were rather repurposed based on their well-established efficacy against other apicomplexan parasites. However, these compounds are associated with mild or severe adverse events and a rapid emergence of drug resistance, thus highlighting the need for new therapeutic strategies that are specifically tailored to Babesia parasites. Herein, we review ongoing babesiosis therapeutic and management strategies and their limitations, and further review current efforts to develop new, effective, and safer therapies for the treatment of this disease.


2019 ◽  
Vol 2 (3) ◽  
pp. e201900382 ◽  
Author(s):  
Jose Thekkiniath ◽  
Nicole Kilian ◽  
Lauren Lawres ◽  
Meital A Gewirtz ◽  
Morven M Graham ◽  
...  

The apicomplexan parasite Babesia microti is the primary agent of human babesiosis, a malaria-like illness and potentially fatal tick-borne disease. Unlike its close relatives, the agents of human malaria, B. microti develops within human and mouse red blood cells in the absence of a parasitophorous vacuole, and its secreted antigens lack trafficking motifs found in malarial secreted antigens. Here, we show that after invasion of erythrocytes, B. microti undergoes a major morphogenic change during which it produces an interlacement of vesicles (IOV); the IOV system extends from the plasma membrane of the parasite into the cytoplasm of the host erythrocyte. We developed antibodies against two immunodominant antigens of the parasite and used them in cell fractionation studies and fluorescence and immunoelectron microscopy analyses to monitor the mode of secretion of B. microti antigens. These analyses demonstrate that the IOV system serves as a major export mechanism for important antigens of B. microti and represents a novel mechanism for delivery of parasite effectors into the host by this apicomplexan parasite.


2007 ◽  
Author(s):  
Andrew J. Plantinga ◽  
Ralph J. Alig ◽  
Henry Eichman ◽  
David J. Lewis

Sign in / Sign up

Export Citation Format

Share Document